NervGen Pharma (TSE:NGEN) has released an update.
NervGen Pharma Corp., a biotech firm focusing on nervous system repair treatments, will present a corporate update at the upcoming 2nd Annual Spinal Cord Injury Investor Symposium. The company’s lead drug candidate, NVG-291, has gained Fast Track Designation by the FDA for spinal cord injury and is currently in Phase 1b/2a clinical trials. The event marks a significant platform for NervGen to share progress and insights with investors and industry stakeholders.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
